Recently, a neuroendocrine-like molecular subtype has been discovered in muscle-invasive urothelial bladder cancer BC. Chromogranin A CGA is a widely used tissue and serum marker in neuroendocrine tumors. Our aim was to evaluate serum CGA sCGA concentrations and their associations with clinical and follow-up data in BC and renal cell carcinoma RCC. sCGA concentrations were analyzed in the following cohorts: 1 BC training set n = 188, 2 BC validation set n = 125, 3 RCC patients n = 77, 4 healthy controls n = 97. CGA immunohistochemistry and RT-qPCR analyses were performed in 20 selected FFPE and 29 frozen BC tissue samples. Acquired data were correlated with clinicopathological parameters including comorbidities with known effect on sCGA as well as with patients’ follow-up data. sCGA levels were signific antly higher in BC but not in RCC patients compared to healthy controls. High sCGA levels were independently associated with poor overall and disease-specific survival both in the BC training P < 0.001, P = 0.002 and validation set P = 0.009, P = 0.017. sCGA levels were inversely correlated with glomerulus filtrating rate GFR and linearly correlated wi th creatinine clearance and urea concentrations. These correlations were not related to the prognostic value of sCGA. Tissue CGA levels were low to absent independently of sCGA concentrations. Our results demonstrate elevated levels and an independent prognostic value for sCGA in BC but not in RCC. Despite the significant correlation between sCGA and GFR , the prognostic relevance of sCGA seems not related to impaired renal function or other comorbidities.
- Bladder cancer
- Chromogranin A
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism